Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study
Abstract
Introduction: Insights into real-world treatment of atopic dermatis (AD) are relevant to clinical decision making. The aim of this analysis was to charakterize patients who receive dupilumab for AD in real-world setting.
Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receiveč dupilumab according to ciuntry-specific prescribing information. We report baseline characteristics, comorbidites and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022.
Analyses are descriptive; no formal statistical comparisons were performed. Results: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD.
Patients had a high disease burden before starting dupilumab: (mean standard deviation) percent body surface area affected (44.8, 24.42, Eczema Area and Severity Index total score (24.8, 12.95, SCORing Atopic Dermatitis total score (60.5 - 19.34, Patient-Oriented Eczema Measure total score (19.7 - 6.37) and Dermatology Life Quality Index total score (13.7 [7.02]. Overall, 741 (77 %) patients reported 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7 %], asthma (323 [33.9 %], food allergy (294 [30.9 %] or anothert allergy (274 [28.8 %].
In the previous 12 months, 310 (32.6 %) patients had received systemic non-steroidal immunosuppressant and 169 (17.8 %) systemic corticosteroids; 141 (14.8 %) had received topical calcineurin inhibitors and 32 (3.4 %) ultraviolet therapy. Most (713 [74.9 %] patients started dupilumab because of prior treatment failure.
Conclusion: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic AD treatments. Clinical Trial Registration: ClinicalTrials.gov identifier NCT03992417.